Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Inclusion criteria

• Healthy male or female subjects aged 20 to 50 years, inclusive, at the time of informed consent.
• Subjects must be in good health as determined by the Investigator based on detailed medical history, physical examination, vital signs, clinical laboratory tests, ECGs and other screening evaluations.
• Ability to provide written informed consent and complying with all study requirements and restrictions.
• Is a non-smoker and non-tobacco user for a minimum of 6 months prior to screening

Exclusion criteria

• History or current evidence of any clinically significant cardiac, endocrinologic, hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator
• Previous treatment with any GH Releasing Hormone (GHRH) analog.
• Participation in another clinical trial or treatment with an investigational agent within 30 days or 5 half-lives, whichever is longer, prior to enrollment.
• History of cancer within the past five years (excluding non-melanoma skin cancer).
• History of alcohol or drug abuse or dependence within 12 months of screening as determined by the Investigator.
• Subjects with a body weight > 120 kg.